FLUARIX TETRA

This brand name is authorized in Austria, Brazil, Estonia, Finland, Hong Kong SAR China, Ireland, Israel, Lithuania, Malta, New Zealand, Poland, Singapore, Spain, Turkey, UK.

Active ingredients

The drug FLUARIX TETRA contains a combination of these active pharmaceutical ingredients (APIs):

1	A/Victoria/4897/2022 (H1N1)pdm09-like strain (A/Victoria/4897/2022, IVR-238)
	Read more about Influenza, inactivated, split virus
2	A/Darwin/9/2021 (H3N2)-like strain (A/Darwin/6/2021, IVR-227)
	Read more about Influenza, inactivated, split virus
3	B/Austria/1359417/2021-like strain (B/Austria/1359417/2021, BVR-26)
	Read more about Influenza, inactivated, split virus
4	B/Phuket/3073/2013-like strain (B/Phuket/3073/2013, wild type)
	Read more about Influenza, inactivated, split virus

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J07BB02	Influenza, purified antigen	J Antiinfectives for systemic use → J07 Vaccines → J07B Viral vaccines → J07BB Influenza vaccines
Discover more medicines within J07BB02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	510615110054302, 510615110054402
EE	Ravimiamet	1763850, 1763861
ES	Centro de información online de medicamentos de la AEMPS	78568
FI	Lääkealan turvallisuus- ja kehittämiskeskus	507366, 517806
GB	Medicines & Healthcare Products Regulatory Agency	252565
HK	Department of Health Drug Office	62234, 62235, 63226
IL	מִשְׂרַד הַבְּרִיאוּת	7676
LT	Valstybinė vaistų kontrolės tarnyba	1085809, 1085810, 1085811, 1085812, 1085813
MT	Medicines Authority	MA170/01101
NZ	Medicines and Medical Devices Safety Authority	16664
PL	Rejestru Produktów Leczniczych	100402273
SG	Health Sciences Authority	14760P
TR	İlaç ve Tıbbi Cihaz Kurumu	8699522964413, 8699522964437